Abstract 114P
Background
Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor that negatively regulates T cell activation and inhibits the immune microenvironment. We explored the prognostic effect of LAG-3-positive tumor-infiltrating lymphocytes (TILs) in metastasis colorectal cancer (mCRC) and its correlation with important genomic alterations of mCRC.
Methods
A total of 139 patients with mCRC were enrolled. Tissues from both the primary tumor and distant metastasis were evaluated for LAG-3 expression by immunohistochemical (IHC) staining. LAG-3 staining of TILs in either the tumor front or tumor center were considered positive. The level of LAG-3 expression was reported as the number of LAG-3-positive immune cells in one high-power field (HPF).
Results
LAG-3 expression was evaluated in 116 primary and 98 metastatic tumor samples. The level of LAG3 expression was higher in the primary tumors compared to the metastatic tumors (median 1.35 vs. 0.55/HPF, p = 0.033). We analyzed the clinicopathologic feature in populations with different levels of LAG3 expression (LAG-3+ TIL >0 vs. =0/HPF; ≥1 vs. <1; ≥3 vs. <3; ≥5 vs. <5; ≥10 vs. <10) in primary and metastatic tumor, respectively. In patients with primary tumors of LAG-3+ TIL >0, there was higher percentage of RAS mutation [54% vs. 20%, p= 0.007]. Patients with primary tumors of LAG-3+ TIL ≥5 more frequently exhibited high tumor mutation burden (TMB ≥10 mutations/mb) tumor than those of LAG-3+ TIL <5 [18% vs. 3%, p= 0.0036]. In subgroups of primary tumors with LAG-3 expression of 3, 5 and 10 or greater, overall survival (OS) were shorter than those with LAG-3 expression less than 3, 5 and 10, respectively [median: LAG-3+ TIL ≥3 vs. <3, 30.1 vs. 45.2 months, Hazard ratio (HR) 1.687, p = 0.035; ≥5 vs. <5, 28.3 vs. 44.6 months, HR 1.791, p = 0.025; ≥10 vs. <10, 28.0 vs. 45.2 months, HR 2.137, p = 0.0073]. This difference was not observed in metastatic tumors. Notably, in metastatic tumors, OS was longer in the LAG-3 >0 than LAG-3=0 group (51.9 vs. 32.5 months, HR 0.513, p = 0.0208).
Conclusions
LAG-3 expression level in primary CRC tumor was associated with negative survival outcome and can serve as a potential prognostic marker. Further studies are needed to explore the optimal cutoff level to identify the candidates that benefit most from LAG-3 blockade.
Clinical trial identification
B-ER-110-172; 23 June 2021.
Editorial acknowledgement
Legal entity responsible for the study
National Cheng Kung University Hospital.
Funding
National Cheng Kung University Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract